董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Donald R. Chase | 男 | Chairman of the Board and Director | 79 | 11.18万美元 | 1.25 | 2026-06-09 |
| Neil Dey | 男 | Chief Executive officer and Director and President and Principal Financial and Accounting Officer | 62 | 47.36万美元 | 未持股 | 2026-06-09 |
| Douglas C. Wurth | 男 | Director | 61 | 11.04万美元 | 1.26 | 2026-06-09 |
| Svetlana Dey | 女 | Director | 54 | 6.25万美元 | 1.26 | 2026-06-09 |
| Fred S. Zeidman | 男 | Director | 79 | 9.31万美元 | 1.25 | 2026-06-09 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Neil Dey | 男 | Chief Executive officer and Director and President and Principal Financial and Accounting Officer | 62 | 47.36万美元 | 未持股 | 2026-06-09 |
董事简历
中英对照 | 中文 | 英文- Donald R. Chase
-
Donald R. Chase，自1972年起在Westbank任职，并担任若干不同级别的职务。1987年， Mr. Chase被任命为Westban董事会董事，1988年12月被任命为总裁兼首席执行官。1990年9月，In September 1990 Mr. Chase被任命为Westbank Corporatio董事和公司总裁兼首席执行官。
Donald R. Chase has served on Bluejay Diagnostics, Inc.'s Board since 2017, and has served as Chairman of the Board since 2025. Mr. Chase has been a member of the Board of Directors of Millyard Bank since 2020. Mr. Chase was a member of the Board of Directors of Merchants Bank and Merchants Bancshares, Inc., in South Burlington. VT, from 2015 through 2017. Mr. Chase was Chairman of the Board of NUVO Bank and Trust Company of Springfield, Massachusetts since its inception in 2008 through 2015. Mr. Chase served as President and Chief Executive Officer, Vice Chairman, and a Director of Westbank Corporation and its wholly owned subsidiary, Westbank from 1988 to 2007. Mr. Chase is active in a number of commercial real estate, farming and ranching activities and serves in a number of civic roles. He is former Chairman of the Board of Trustees for the Eastern States Exposition in West Springfield, MA. Mr. Chase is also a commissioner of the Board of Public Safety for the City of West Springfield, MA and is a former member of the Massachusetts Board of Agriculture. Mr. Chase is a veteran of the United States Army during which he served in combat in Vietnam from 1967 through 1969. Mr. Chase graduated with honors from Western New England University with a Bachelor of Science degree in Accounting. - Donald R. Chase，自1972年起在Westbank任职，并担任若干不同级别的职务。1987年， Mr. Chase被任命为Westban董事会董事，1988年12月被任命为总裁兼首席执行官。1990年9月，In September 1990 Mr. Chase被任命为Westbank Corporatio董事和公司总裁兼首席执行官。
- Donald R. Chase has served on Bluejay Diagnostics, Inc.'s Board since 2017, and has served as Chairman of the Board since 2025. Mr. Chase has been a member of the Board of Directors of Millyard Bank since 2020. Mr. Chase was a member of the Board of Directors of Merchants Bank and Merchants Bancshares, Inc., in South Burlington. VT, from 2015 through 2017. Mr. Chase was Chairman of the Board of NUVO Bank and Trust Company of Springfield, Massachusetts since its inception in 2008 through 2015. Mr. Chase served as President and Chief Executive Officer, Vice Chairman, and a Director of Westbank Corporation and its wholly owned subsidiary, Westbank from 1988 to 2007. Mr. Chase is active in a number of commercial real estate, farming and ranching activities and serves in a number of civic roles. He is former Chairman of the Board of Trustees for the Eastern States Exposition in West Springfield, MA. Mr. Chase is also a commissioner of the Board of Public Safety for the City of West Springfield, MA and is a former member of the Massachusetts Board of Agriculture. Mr. Chase is a veteran of the United States Army during which he served in combat in Vietnam from 1967 through 1969. Mr. Chase graduated with honors from Western New England University with a Bachelor of Science degree in Accounting.
- Neil Dey
-
Neil Dey co于2015年创立Bluejay Diagnostics，曾担任Bluejay Diagnostics, Inc.总裁、首席执行官（我们的首席执行官），此后一直担任董事。自2024年3月29日起，他还成为Bluejay Diagnostics, Inc.的首席财务和会计官。2008年，Dey Co先生创立了Lana Management and Business Research International，LLC（“LMBRI”），并在2008年至2015年期间担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国、日本和欧盟医疗领域的产品发布和营销。除了继续担任LMBRI的经理外，他还担任Laminar Pharma，Inc.的董事和高级管理人员，该公司是位于西班牙的Laminar Pharma的美国子公司，该公司专注于开发基于膜脂疗法的癌症疗法。在担任LMBRI首席运营官期间，他花了大约八年时间为东丽工业、日立化学（现为昭和电工材料有限公司）、富士胶片（富士化学）、默沙东公司、上实国际等提供咨询服务。2005年至2007年，Dey先生担任Definines，AG业务发展和市场副总裁。从2001年到2005年，Dey先生担任IMPATH，Inc.的美国西部业务发展主管，负责三个业务部门和引入Her2neu诊断用于赫赛汀治疗乳腺癌。此前的职位包括Genmethrax，Inc.首席商务官；Thomas Jefferson医科大学技术许可经理；Ciba Geigy（诺华）技术许可经理。Dey先生在印度Visva Bharati大学获得生物化学理学学士和理学硕士学位，并在匈牙利生物研究中心获得脂质膜生物化学博士学位。他还获得了剑桥大学工商管理硕士学位（富布赖特奖学金）。
Neil Dey co founded Bluejay Diagnostics in 2015 and has served as Bluejay Diagnostics, Inc.'s President, Chief Executive officer (our principal executive officer) and as a Director since then. Effective as of March 29, 2024, he also became Bluejay Diagnostics, Inc.'s principal financial and accounting officer. In 2008, Mr. Dey co founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and the EU. In addition to continuing to serve as a manager of LMBRI, he also serves as a director and officer of Laminar Pharma, Inc., the U.S. subsidiary of Spain based Laminar Pharma, a company focused on developing cancer therapy based on membrane lipid therapy. During his tenure as Chief Operating Officer of LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's degree in Business Administration (Fulbright Scholarship) from the University of Cambridge. - Neil Dey co于2015年创立Bluejay Diagnostics，曾担任Bluejay Diagnostics, Inc.总裁、首席执行官（我们的首席执行官），此后一直担任董事。自2024年3月29日起，他还成为Bluejay Diagnostics, Inc.的首席财务和会计官。2008年，Dey Co先生创立了Lana Management and Business Research International，LLC（“LMBRI”），并在2008年至2015年期间担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国、日本和欧盟医疗领域的产品发布和营销。除了继续担任LMBRI的经理外，他还担任Laminar Pharma，Inc.的董事和高级管理人员，该公司是位于西班牙的Laminar Pharma的美国子公司，该公司专注于开发基于膜脂疗法的癌症疗法。在担任LMBRI首席运营官期间，他花了大约八年时间为东丽工业、日立化学（现为昭和电工材料有限公司）、富士胶片（富士化学）、默沙东公司、上实国际等提供咨询服务。2005年至2007年，Dey先生担任Definines，AG业务发展和市场副总裁。从2001年到2005年，Dey先生担任IMPATH，Inc.的美国西部业务发展主管，负责三个业务部门和引入Her2neu诊断用于赫赛汀治疗乳腺癌。此前的职位包括Genmethrax，Inc.首席商务官；Thomas Jefferson医科大学技术许可经理；Ciba Geigy（诺华）技术许可经理。Dey先生在印度Visva Bharati大学获得生物化学理学学士和理学硕士学位，并在匈牙利生物研究中心获得脂质膜生物化学博士学位。他还获得了剑桥大学工商管理硕士学位（富布赖特奖学金）。
- Neil Dey co founded Bluejay Diagnostics in 2015 and has served as Bluejay Diagnostics, Inc.'s President, Chief Executive officer (our principal executive officer) and as a Director since then. Effective as of March 29, 2024, he also became Bluejay Diagnostics, Inc.'s principal financial and accounting officer. In 2008, Mr. Dey co founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and the EU. In addition to continuing to serve as a manager of LMBRI, he also serves as a director and officer of Laminar Pharma, Inc., the U.S. subsidiary of Spain based Laminar Pharma, a company focused on developing cancer therapy based on membrane lipid therapy. During his tenure as Chief Operating Officer of LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's degree in Business Administration (Fulbright Scholarship) from the University of Cambridge.
- Douglas C. Wurth
-
Douglas C. Wurth自2017年起在Bluejay Diagnostics, Inc.董事会任职，并于2017年至2025年担任董事会主席。自2016年以来，Wurth先生一直是一名私人投资者。Wurth先生于2021年2月至2022年5月担任Good Works II Acquisition Corp.的首席执行官和董事，并于2020年10月至2021年8月担任Good Works Acquisition Corp.的联席主席。Wurth先生在1997年至2016年任职于摩根大通的近20年期间，在摩根大通资产管理公司领导了主要业务。Wurth先生曾是另类投资资产管理公司的首席执行官，也是摩根大通国际私人银行的首席执行官，在纽约、香港和伦敦工作期间，他领导了该业务在亚洲、拉丁美洲和欧洲的扩张。自离开摩根大通以来，Wurth先生投资并帮助领导了几家私营公司，包括Standard Power和Vestrata，他是这两家公司的董事会主席，他是Triax Technologies的董事会成员。在加入摩根大通之前，Wurth先生于1992年至1995年在纽约Skadden，Arps，Slate，Meagher & Flom公司从事法律工作，并担任前美国参议员罗伯特·多尔1996年总统竞选活动的总法律顾问。Wurth先生获得了圣母大学的文学学士学位和弗吉尼亚大学法学院的法学博士学位。
Douglas C. Wurth has served on Bluejay Diagnostics, Inc.'s Board since 2017, and served as Chairman of the Board from 2017 to 2025. Since 2016, Mr. Wurth has been a private investor. Mr. Wurth has served as Chief Executive Officer and a Director of Good Works II Acquisition Corp. from February 2021 to May 2022, and as Co Chairman of Good Works Acquisition Corp. from October 2020 to August 2021. Mr. Wurth led major businesses within J.P. Morgan Asset Management during his nearly 20 years at J.P Morgan from 1997 to 2016. Mr. Wurth was the Chief Executive Officer of Alternative Investments in Asset Management, and Chief Executive Officer of J.P. Morgan's International Private Bank, where he led the expansion of the franchise in Asia, Latin America and Europe while based in New York, Hong Kong, and London. Since leaving J.P. Morgan, Mr. Wurth has invested in and helped lead several private companies, including Standard Power and Vestrata, both of which he is Chairman of the Board of, and he is a board member of Triax Technologies. Before joining J.P. Morgan, Mr. Wurth practiced law at the New York firm Skadden, Arps, Slate, Meagher & Flom from 1992 to 1995, and served as General Counsel to former U.S. Senator Robert Dole's 1996 presidential campaign. Mr. Wurth earned a Bachelor of Arts degree from the University of Notre Dame and a J.D. from the University of Virginia School of Law. - Douglas C. Wurth自2017年起在Bluejay Diagnostics, Inc.董事会任职，并于2017年至2025年担任董事会主席。自2016年以来，Wurth先生一直是一名私人投资者。Wurth先生于2021年2月至2022年5月担任Good Works II Acquisition Corp.的首席执行官和董事，并于2020年10月至2021年8月担任Good Works Acquisition Corp.的联席主席。Wurth先生在1997年至2016年任职于摩根大通的近20年期间，在摩根大通资产管理公司领导了主要业务。Wurth先生曾是另类投资资产管理公司的首席执行官，也是摩根大通国际私人银行的首席执行官，在纽约、香港和伦敦工作期间，他领导了该业务在亚洲、拉丁美洲和欧洲的扩张。自离开摩根大通以来，Wurth先生投资并帮助领导了几家私营公司，包括Standard Power和Vestrata，他是这两家公司的董事会主席，他是Triax Technologies的董事会成员。在加入摩根大通之前，Wurth先生于1992年至1995年在纽约Skadden，Arps，Slate，Meagher & Flom公司从事法律工作，并担任前美国参议员罗伯特·多尔1996年总统竞选活动的总法律顾问。Wurth先生获得了圣母大学的文学学士学位和弗吉尼亚大学法学院的法学博士学位。
- Douglas C. Wurth has served on Bluejay Diagnostics, Inc.'s Board since 2017, and served as Chairman of the Board from 2017 to 2025. Since 2016, Mr. Wurth has been a private investor. Mr. Wurth has served as Chief Executive Officer and a Director of Good Works II Acquisition Corp. from February 2021 to May 2022, and as Co Chairman of Good Works Acquisition Corp. from October 2020 to August 2021. Mr. Wurth led major businesses within J.P. Morgan Asset Management during his nearly 20 years at J.P Morgan from 1997 to 2016. Mr. Wurth was the Chief Executive Officer of Alternative Investments in Asset Management, and Chief Executive Officer of J.P. Morgan's International Private Bank, where he led the expansion of the franchise in Asia, Latin America and Europe while based in New York, Hong Kong, and London. Since leaving J.P. Morgan, Mr. Wurth has invested in and helped lead several private companies, including Standard Power and Vestrata, both of which he is Chairman of the Board of, and he is a board member of Triax Technologies. Before joining J.P. Morgan, Mr. Wurth practiced law at the New York firm Skadden, Arps, Slate, Meagher & Flom from 1992 to 1995, and served as General Counsel to former U.S. Senator Robert Dole's 1996 presidential campaign. Mr. Wurth earned a Bachelor of Arts degree from the University of Notre Dame and a J.D. from the University of Virginia School of Law.
- Svetlana Dey
-
Svetlana Dey自2015年起担任BlueJay的董事会成员。Dey Co女士于2015年创立了Bluejay Diagnostics。她还于2008年共同创立了LMBRI，这是一家管理咨询公司，专注于美国、日本和印度医疗领域的产品发布和营销。Dey女士自2008年起担任LMBRI总裁兼首席执行官。此外，她还担任Laminar Pharma，Inc.的董事，该公司是西班牙Laminar Pharma的美国子公司，该公司专注于开发基于膜脂疗法的癌症疗法。在加入LMBRI之前，Dey女士在医疗保健咨询业务领域工作了超过15年。在这些角色中，她参与了医疗保健和生命科学产品开发、销售和营销运营以及一般管理的管理和运营。Dey女士获得了俄罗斯马里埃尔共和国国立大学的数学硕士学位。
Svetlana Dey has been member of Bluejay's Board since 2015. Ms. Dey co founded Bluejay Diagnostics in 2015. She also co founded LMBRI in 2008, a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and India. Ms. Dey has served as LMBRI's President and CEO since 2008. In addition, she serves as a director of Laminar Pharma, Inc., the U.S. subsidiary of Spain based Laminar Pharma, a company focused on developing cancer therapy based on membrane lipid therapy. Prior to LMBRI, Ms. Dey spent more than 15 years in healthcare consulting businesses. In these roles, she has been involved in management and operations of healthcare and life sciences products development, sales and marketing operations and general management. Ms. Dey earned a Master's Degree in Mathematics from the State University of Mari El Republic, Russia. - Svetlana Dey自2015年起担任BlueJay的董事会成员。Dey Co女士于2015年创立了Bluejay Diagnostics。她还于2008年共同创立了LMBRI，这是一家管理咨询公司，专注于美国、日本和印度医疗领域的产品发布和营销。Dey女士自2008年起担任LMBRI总裁兼首席执行官。此外，她还担任Laminar Pharma，Inc.的董事，该公司是西班牙Laminar Pharma的美国子公司，该公司专注于开发基于膜脂疗法的癌症疗法。在加入LMBRI之前，Dey女士在医疗保健咨询业务领域工作了超过15年。在这些角色中，她参与了医疗保健和生命科学产品开发、销售和营销运营以及一般管理的管理和运营。Dey女士获得了俄罗斯马里埃尔共和国国立大学的数学硕士学位。
- Svetlana Dey has been member of Bluejay's Board since 2015. Ms. Dey co founded Bluejay Diagnostics in 2015. She also co founded LMBRI in 2008, a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and India. Ms. Dey has served as LMBRI's President and CEO since 2008. In addition, she serves as a director of Laminar Pharma, Inc., the U.S. subsidiary of Spain based Laminar Pharma, a company focused on developing cancer therapy based on membrane lipid therapy. Prior to LMBRI, Ms. Dey spent more than 15 years in healthcare consulting businesses. In these roles, she has been involved in management and operations of healthcare and life sciences products development, sales and marketing operations and general management. Ms. Dey earned a Master's Degree in Mathematics from the State University of Mari El Republic, Russia.
- Fred S. Zeidman
-
Fred S. Zeidman，自2011年9月以来一直是Petroflow能源公司的董事长，以及自2013年4月以来一直在Petro River Oil Corporation公司任董事。自2009年以来任Hyperdynamics公司的董事，自1986年以来任Prosperity Bancshares股份有限公司的董事。自2004年以来一直是Are一家misSoft Liquidating Trust的一位受托人。2013年3月，被任命为Nova Biosource Fuels, Inc. （"Nova"）（一家公开上市的生物石油科技公司）的临时总裁，并一直任到2009年11月该公司的收购。Zeidman先生还曾于2007年6月-2009年11月期间，在Nova任董事。2009年8月-2009年11月期间，他曾在Transmeridian Exploration股份有限公司任首席重组官，并且一直任到2009年11月该公司的售出。他曾在Prosperity Bank工作了26年。他还曾于2002年6月一直到2007年2月Seitel股份有限公司售出之前，在Seitel 股份有限公司（一家油田服务公司）任首席执行官、总裁兼董事长。2003年7月-2008年12月期间，在Greenberg Traurig律师事务所任总经理。他曾在各种公司担任首席执行官、临时首席执行官以及董事长，包括若干石油和天然气行业的公司。他目前是美国（U.S。） Holocaust Memorial Council的一位荣誉董事长，是于2002年3月被前总裁t George W. Bush任命为到这个职位上的，任期为2002-2010年。他目前还是Houston 德州（Texas）大学卫生科学系统的一位荣誉主席，并且在德州（Texas）心脏研究所（在那里他目前任财务总监）以及the Institute for Rehabilitation and Research （TIRR）的理事会任职他目前在Saint Thomas大学的理事会和执行委员会任职，并且管理着其发展委员会和Houston社区学院。他是在Washington大学获得文学学士学位，以及在New York大学获得工商管理学硕士学位 的。
Fred S. Zeidman has served on Bluejay Diagnostics, Inc.'s Board since May 2021. Mr. Zeidman is Chairman of WoodRock & Co., an investment banking service business. Mr. Zeidman served as Co Chairman and CEO of publicly traded SPAC Good Works Acquisition Corp. from June 2020 until its acquisition by Cipher Mining Technologies Inc. in August 2021, and Chairman of Good Works II Acquisition Corp. from February 2021 until its deregistration in August 2023. Mr. Zeidman also previously served as Chairman of Gordian Group LLC, a U.S. investment bank specializing in board level advice in complex, distressed or "story" financial matters. Mr. Zeidman, Chairman Emeritus of the United States Holocaust Memorial Council was appointed by President George W. Bush in March 2002 and served as Chair from 2002 2010. A prominent Houston based business and civic leader, Mr. Zeidman also is Chairman Emeritus of the University of Texas Health Science System Houston. He was National Chairman of the Development Corp of Israel Campaign (Israel Bonds) and served on the Board of the National World War II Museum. Mr. Zeidman was the former CEO, President and Chairman of Seitel, Inc., a Houston based onshore seismic data provider where he was instrumental in the successful turnaround of the Company. He served as lead Director of Straight Path Communications, Inc. until its sale to Verizon in 2018. He was also Director of REMA, a division of NRG Corp. and he further serves on the board of Prosperity Bank and was formerly Restructuring Officer of TransMeridian Exploration Inc. and Chief Bankruptcy Trustee of AremisSoft Corp. He held the post of Chairman of the Board and CEO of Unibar Corporation, the largest domestic independent drilling fluids company, until its sale to Anchor Drilling Fluids in 1992. Mr. Zeidman holds a Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University. - Fred S. Zeidman，自2011年9月以来一直是Petroflow能源公司的董事长，以及自2013年4月以来一直在Petro River Oil Corporation公司任董事。自2009年以来任Hyperdynamics公司的董事，自1986年以来任Prosperity Bancshares股份有限公司的董事。自2004年以来一直是Are一家misSoft Liquidating Trust的一位受托人。2013年3月，被任命为Nova Biosource Fuels, Inc. （"Nova"）（一家公开上市的生物石油科技公司）的临时总裁，并一直任到2009年11月该公司的收购。Zeidman先生还曾于2007年6月-2009年11月期间，在Nova任董事。2009年8月-2009年11月期间，他曾在Transmeridian Exploration股份有限公司任首席重组官，并且一直任到2009年11月该公司的售出。他曾在Prosperity Bank工作了26年。他还曾于2002年6月一直到2007年2月Seitel股份有限公司售出之前，在Seitel 股份有限公司（一家油田服务公司）任首席执行官、总裁兼董事长。2003年7月-2008年12月期间，在Greenberg Traurig律师事务所任总经理。他曾在各种公司担任首席执行官、临时首席执行官以及董事长，包括若干石油和天然气行业的公司。他目前是美国（U.S。） Holocaust Memorial Council的一位荣誉董事长，是于2002年3月被前总裁t George W. Bush任命为到这个职位上的，任期为2002-2010年。他目前还是Houston 德州（Texas）大学卫生科学系统的一位荣誉主席，并且在德州（Texas）心脏研究所（在那里他目前任财务总监）以及the Institute for Rehabilitation and Research （TIRR）的理事会任职他目前在Saint Thomas大学的理事会和执行委员会任职，并且管理着其发展委员会和Houston社区学院。他是在Washington大学获得文学学士学位，以及在New York大学获得工商管理学硕士学位 的。
- Fred S. Zeidman has served on Bluejay Diagnostics, Inc.'s Board since May 2021. Mr. Zeidman is Chairman of WoodRock & Co., an investment banking service business. Mr. Zeidman served as Co Chairman and CEO of publicly traded SPAC Good Works Acquisition Corp. from June 2020 until its acquisition by Cipher Mining Technologies Inc. in August 2021, and Chairman of Good Works II Acquisition Corp. from February 2021 until its deregistration in August 2023. Mr. Zeidman also previously served as Chairman of Gordian Group LLC, a U.S. investment bank specializing in board level advice in complex, distressed or "story" financial matters. Mr. Zeidman, Chairman Emeritus of the United States Holocaust Memorial Council was appointed by President George W. Bush in March 2002 and served as Chair from 2002 2010. A prominent Houston based business and civic leader, Mr. Zeidman also is Chairman Emeritus of the University of Texas Health Science System Houston. He was National Chairman of the Development Corp of Israel Campaign (Israel Bonds) and served on the Board of the National World War II Museum. Mr. Zeidman was the former CEO, President and Chairman of Seitel, Inc., a Houston based onshore seismic data provider where he was instrumental in the successful turnaround of the Company. He served as lead Director of Straight Path Communications, Inc. until its sale to Verizon in 2018. He was also Director of REMA, a division of NRG Corp. and he further serves on the board of Prosperity Bank and was formerly Restructuring Officer of TransMeridian Exploration Inc. and Chief Bankruptcy Trustee of AremisSoft Corp. He held the post of Chairman of the Board and CEO of Unibar Corporation, the largest domestic independent drilling fluids company, until its sale to Anchor Drilling Fluids in 1992. Mr. Zeidman holds a Bachelor's degree from Washington University in St. Louis and a Master's in Business Administration from New York University.
高管简历
中英对照 | 中文 | 英文- Neil Dey
Neil Dey co于2015年创立Bluejay Diagnostics，曾担任Bluejay Diagnostics, Inc.总裁、首席执行官（我们的首席执行官），此后一直担任董事。自2024年3月29日起，他还成为Bluejay Diagnostics, Inc.的首席财务和会计官。2008年，Dey Co先生创立了Lana Management and Business Research International，LLC（“LMBRI”），并在2008年至2015年期间担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国、日本和欧盟医疗领域的产品发布和营销。除了继续担任LMBRI的经理外，他还担任Laminar Pharma，Inc.的董事和高级管理人员，该公司是位于西班牙的Laminar Pharma的美国子公司，该公司专注于开发基于膜脂疗法的癌症疗法。在担任LMBRI首席运营官期间，他花了大约八年时间为东丽工业、日立化学（现为昭和电工材料有限公司）、富士胶片（富士化学）、默沙东公司、上实国际等提供咨询服务。2005年至2007年，Dey先生担任Definines，AG业务发展和市场副总裁。从2001年到2005年，Dey先生担任IMPATH，Inc.的美国西部业务发展主管，负责三个业务部门和引入Her2neu诊断用于赫赛汀治疗乳腺癌。此前的职位包括Genmethrax，Inc.首席商务官；Thomas Jefferson医科大学技术许可经理；Ciba Geigy（诺华）技术许可经理。Dey先生在印度Visva Bharati大学获得生物化学理学学士和理学硕士学位，并在匈牙利生物研究中心获得脂质膜生物化学博士学位。他还获得了剑桥大学工商管理硕士学位（富布赖特奖学金）。
Neil Dey co founded Bluejay Diagnostics in 2015 and has served as Bluejay Diagnostics, Inc.'s President, Chief Executive officer (our principal executive officer) and as a Director since then. Effective as of March 29, 2024, he also became Bluejay Diagnostics, Inc.'s principal financial and accounting officer. In 2008, Mr. Dey co founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and the EU. In addition to continuing to serve as a manager of LMBRI, he also serves as a director and officer of Laminar Pharma, Inc., the U.S. subsidiary of Spain based Laminar Pharma, a company focused on developing cancer therapy based on membrane lipid therapy. During his tenure as Chief Operating Officer of LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's degree in Business Administration (Fulbright Scholarship) from the University of Cambridge.- Neil Dey co于2015年创立Bluejay Diagnostics，曾担任Bluejay Diagnostics, Inc.总裁、首席执行官（我们的首席执行官），此后一直担任董事。自2024年3月29日起，他还成为Bluejay Diagnostics, Inc.的首席财务和会计官。2008年，Dey Co先生创立了Lana Management and Business Research International，LLC（“LMBRI”），并在2008年至2015年期间担任LMBRI的首席运营官。LMBRI是一家管理咨询公司，专注于美国、日本和欧盟医疗领域的产品发布和营销。除了继续担任LMBRI的经理外，他还担任Laminar Pharma，Inc.的董事和高级管理人员，该公司是位于西班牙的Laminar Pharma的美国子公司，该公司专注于开发基于膜脂疗法的癌症疗法。在担任LMBRI首席运营官期间，他花了大约八年时间为东丽工业、日立化学（现为昭和电工材料有限公司）、富士胶片（富士化学）、默沙东公司、上实国际等提供咨询服务。2005年至2007年，Dey先生担任Definines，AG业务发展和市场副总裁。从2001年到2005年，Dey先生担任IMPATH，Inc.的美国西部业务发展主管，负责三个业务部门和引入Her2neu诊断用于赫赛汀治疗乳腺癌。此前的职位包括Genmethrax，Inc.首席商务官；Thomas Jefferson医科大学技术许可经理；Ciba Geigy（诺华）技术许可经理。Dey先生在印度Visva Bharati大学获得生物化学理学学士和理学硕士学位，并在匈牙利生物研究中心获得脂质膜生物化学博士学位。他还获得了剑桥大学工商管理硕士学位（富布赖特奖学金）。
- Neil Dey co founded Bluejay Diagnostics in 2015 and has served as Bluejay Diagnostics, Inc.'s President, Chief Executive officer (our principal executive officer) and as a Director since then. Effective as of March 29, 2024, he also became Bluejay Diagnostics, Inc.'s principal financial and accounting officer. In 2008, Mr. Dey co founded Lana Management and Business Research International, LLC ("LMBRI"), and served as Chief Operating Officer of LMBRI from 2008 through 2015. LMBRI is a management consulting company focused on product launch and marketing in the medical field in the U.S., Japan and the EU. In addition to continuing to serve as a manager of LMBRI, he also serves as a director and officer of Laminar Pharma, Inc., the U.S. subsidiary of Spain based Laminar Pharma, a company focused on developing cancer therapy based on membrane lipid therapy. During his tenure as Chief Operating Officer of LMBRI, he spent approximately eight years consulting with Toray Industries, Hitachi Chemicals (now Showa Denko Materials Co. Ltd.), Fujifilm (Fuji Chemicals), Merck & Co., SRI International, among others. From 2005 to 2007, Mr. Dey served as Vice President of Business Development and Market for Definines, AG. From 2001 to 2005, Mr. Dey served as Head of Business Development, Western U.S. for IMPATH, Inc., where he was responsible for three business units and the introduction of Her2neu diagnostics for breast cancer treatment with Herceptin. Earlier positions include Chief Business Officer for Genmethrax, Inc.; Manager, Technology Licensing, Thomas Jefferson Medical University; and Manager, Technology Licensing, Ciba Geigy (Novartis). Mr. Dey earned both Bachelor of Science and Master of Science degrees in Biochemistry from Visva Bharati University in India and a Ph.D. in Lipid Membrane Biochemistry from Biological Research Center in Hungary. He also earned a Master's degree in Business Administration (Fulbright Scholarship) from the University of Cambridge.